The bottleneck is inside and being paid away

Pacira BioSciences, Inc. (PCRX) — this company's answers

The model's full reasoning — Q4 2017 call → NOWe need to answer YES or NO based only on the transcript. The question asks: Does management convey that the main thing standing between the company and meaningfully more business right now is the company's own capability (capacity, people, facilities, throughput, ability to deliver) rather than demand shortage, AND that they are already spending real money/effort to remove that limit, with business waiting on the other side visible today? We need to find if management says there is live demand pressing in, that the limit is their own capability, and that removal is underway. From transcript: They discuss expanding manufacturing capacity in UK, with first commercial manufacturing on track to begin in second half of 2018. They talk about scale-up of manufacturing capacity. They mention "we have plenty of capacity from our current facilities in San Diego and our online facilities coming late this year in Swindon." They mention "we will give Swindon as much material as they can make, because it is an improved gross margin." They talk about spray process and batch process, patents. But is there any indication that demand exceeds current capability? They guide 2018 sales to $300-310M, which is growth but not necessarily constrained by capacity. They mention "projecting the timing of when each of these items will translate into accelerated growth is difficult to predict" but not about capacity constraint. They mention "we are very confident in the growth initiatives" but not about inability to supply. There is no mention of backorders, waiting customers, inability to meet demand, or that they are allocating output. They talk about expanding capacity but not because they are constrained. They are expanding to improve margins and for future growth, but not because they have more orders than they can fill. The question asks for "live demand pressing in" - actual current behavior like waiting buyers, stretched lead times, allocated output, work queued. None of that appears. They mention sales growth but that's not necessarily pressing against capacity. They talk about manufacturing expansion but it's for margin improvement and future opportunities, not because they can't meet current demand. Thus answer NO.

← Back to the full PCRX analysis